Neumora Therapeutics (NMRA) Operating Expenses (2022 - 2026)

Neumora Therapeutics' Operating Expenses history runs 5 years deep, the most recent figure standing at $52.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 25.48% year-over-year to $52.9 million in Q1 2026; TTM through Mar 2026 was $223.1 million, a 18.68% decrease from a year earlier, with the FY2025 full-year figure at $241.2 million, down 8.47% from the prior year.
• Operating Expenses eased to $52.9 million in Q1 2026 per NMRA's latest filing, from $58.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $114.0 million in Q4 2023 and bottomed at $30.6 million in Q3 2022.
• The 5-year median for Operating Expenses is $57.7 million (2025), against an average of $58.1 million.
• Across the five-year window, Operating Expenses soared 271.13% in 2023 and sank 44.81% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $30.7 million in 2022, then surged by 271.13% to $114.0 million in 2023, then sank by 44.81% to $62.9 million in 2024, then slipped by 7.06% to $58.5 million in 2025, then declined by 9.6% to $52.9 million in 2026.
• Per Business Quant, the three latest NMRA Operating Expenses figures stand at $52.9 million (Q1 2026), $58.5 million (Q4 2025), and $57.7 million (Q3 2025).